NASDAQ:THOR - Synthorx Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$67.99
+0.30 (1.20%)
Get New Synthorx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THOR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Synthorx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $67.99.

This chart shows the closing price for THOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Synthorx. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$23.00 ➝ $68.00Low
12/11/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$68.00Low
12/10/2019HC WainwrightDowngradeBuy ➝ NeutralLow
11/24/2019Evercore ISIReiterated RatingBuy$35.00High
11/11/2019HC WainwrightReiterated RatingBuy$30.00Low
9/18/2019HC WainwrightSet Price TargetBuy$30.00Low
5/1/2019HC WainwrightReiterated RatingBuy$30.00High
3/18/2019SVB LeerinkReiterated RatingOutperformLow
3/15/2019SVB LeerinkInitiated CoverageOutperformHigh
1/2/2019HC WainwrightInitiated CoverageBuy ➝ Buy$30.00High
1/2/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$21.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Synthorx logo
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $67.99
Low: $67.99
High: $67.99

50 Day Range

MA: $67.99
Low: $67.99
High: $67.99

52 Week Range

Now: $67.99
Low: $11.05
High: $71.90

Volume

N/A

Average Volume

474,507 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Synthorx?

The following equities research analysts have issued research reports on Synthorx in the last twelve months:
View the latest analyst ratings for THOR.

What is the current price target for Synthorx?

0 Wall Street analysts have set twelve-month price targets for Synthorx in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synthorx in the next year.
View the latest price targets for THOR.

What is the current consensus analyst rating for Synthorx?

Synthorx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for THOR.

What other companies compete with Synthorx?

How do I contact Synthorx's investor relations team?

Synthorx's physical mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier's listed phone number is 858-750-4700 and its investor relations email address is [email protected] The official website for Synthorx is www.synthorx.com.